Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non-neuropsychiatric SLE?

Lucenir M Silva, Eduardo A Donadi

Abstract

Objectives—To analyse frequency of HLA class II antigens (DR and DQ) and lymphocytoxic autoantibodies in patients with systemic lupus erythematosus (SLE) and subsets with or without neuropsychiatric involvement.

Methods—Ninety three patients with SLE (42 with neuropsychiatric features) were typed for HLA class II antigens and investigated for the presence of lymphocytoxic autoantibodies by a complement dependent microlymphocytotoxicity assay. A total of 191 controls of similar ethnic background were also typed for HLA antigens.

Results—HLA-DR3 antigen was increased in the total group of patients with SLE (p = 0.003) and in the neuropsychiatric group (p = 0.002). HLA-DR4 antigen frequency was increased in non-neuropsychiatric patients (p = 0.001) and decreased in patients with neuropsychiatric SLE (p = 0.0005). Comparisons of HLA frequencies between subgroups of patients showed decreased HLA-DR4 (p < 0.0001) and increased HLA-DR9 and HLA-DQ2 antigens (p = 0.0008 and 0.005 respectively) in the neuropsychiatric group. The frequency of lymphocytoxic autoantibodies was increased in neuropsychiatric patients with SLE having HLA-DR9 specificity (p = 0.04).

Conclusion—HLA-DR4 may have a protective specificity for the development of neuropsychiatric features of SLE and HLA-DR9, in addition to HLA-DR3, and the presence of lymphocytoxic autoantibodies may predispose to neuropsychiatric abnormalities.

Patients and methods

Patients
We studied 93 patients with SLE, diagnosed according to the criteria of the American College of Rheumatology, and seen at the University Hospital of the School of Medicine of Ribeirão Preto, Brazil, from 1991 to 1994. Forty two patients had neuropsychiatric features classified according to a workshop consensus. There were 29 white patients (all of them females), six Afro-European (five females and one male), and seven black patients (six females and one male). Their median age was 34 (range 13–66) years. Fifty one patients did not have neuropsychiatric features, 36 were white (35 female, one male), nine were Afro-European, and six were black with a median age of 30 (range 10–53) years.

Systemic lupus erythematosus (SLE) is a complex multisystemic disease associated with neuropsychiatric abnormalities in more than 50% of patients. The entire nervous system may be affected, with symptoms and signs ranging from focal to diffuse. Generalised seizures, psychosis, transverse myelitis, focal seizures, stroke, peripheral and cranial neuropathies, aseptic meningitis, and movement disorders have been described as characteristic features of neuropsychiatric lupus (NPSLE). Because NPSLE may occur in the absence of generalised disease and in view of the virtual absence of histopathologically documentable vasculitis within the brain, there is controversy as to whether the pathogenesis of NPSLE is different from that of SLE without neuropsychiatric involvement. Autoantibodies that react with neuronal cell membranes, lymphocytoxic antibodies that cross react with brain tissue, and antibrain antibodies that cross react with lymphocytes have been implicated in the pathogenesis of NPSLE. To the other hand, lymphocytoxic serum from patients with SLE exhibits reactivity against β2-microglobulin and HLA class I and II molecules. To explore whether immunogenetic susceptibility to NPSLE is different from SLE without neuropsychiatric features we investigated HLA class II antigens in these SLE subsets. We also evaluated the possible association of HLA antigens and lymphocytoxic autoantibodies.

Control group
A total of 191 healthy blood donors from the same geographic area (79% white, 12% Afro-European, and 9% black), were typed for HLA class II antigens. A total of 30 healthy subjects were also assayed for lymphocytoxic autoantibodies.

HLA class II typing
Total lymphocytes were isolated using a Ficoll-Hypaque gradient at a density of 1.077 g/l. B lymphocytes were obtained by adherence to nylon wool (Robbins Scientific, USA); HLA antisera against DR1-DR18, DR52-DR53,
and DQ1-DQ7 antigens were obtained from Pel Freez, Gene Trak, and Fred Hutchinson Cancer Research Centre (USA), and Biotest (Germany). Serological HLA class II typing was performed with a complement dependent microlymphocytotoxicity assay.11

LYMPHOCYTOTOXIC AUTOANTIBODIES
Blood was drawn from patients with either neuropsychiatric or non-neuropsychiatric active disease. Lymphocytotoxic antibody was detected using the patient's own lymphocytes in a complement dependent microlymphocytotoxicity assay.11 Incubations were performed at room temperature and lymphocytotoxins were considered to be present when there was at least 20% cell lysis.

STATISTICAL ANALYSIS
A two tailed exact Fisher's test was used for comparisons of HLA frequencies, with corrections of the p values according to the number of specificities tested and the number of comparisons made. Differences were considered to be significant at p = 0.05. Relative risk (RR), which indicates how many times more often the disease occurs in people with the HLA antigen compared with those without it, aetiological fraction (EF), which indicates how much the HLA marker contributes to disease at the population level, and preventive fraction (PF), which is an indicator of protection, were also estimated.12

Results
The most frequent neuropsychiatric features were organic brain syndrome (33-3%), psychosis (30-9%), generalised seizures (30-9%), cranial neuropathies (28-6%), stroke (23-8%), peripheral neuropathies (19-1%) half associated with other disorders of the central nervous system and half isolated), aseptic meningitis (9-5%), pseudotumour cerebri (7-1%), and transverse myelitis (4-8%). About 62% of patients presented neuropsychiatric manifestations considered to be of diffuse disease (organic brain syndrome, generalised seizures, psychosis), associated or not with focal disease, and 38% had only manifestations considered to be of focal disease (aseptic meningitis, aseptic meningitis, pseudotumour cerebri, and cranial and peripheral neuropathies). Table 1 shows the additional clinical and laboratory features of the whole group of patients.

Table 2 shows the frequencies of HLA class II antigens. Specificity for HLA-DR3 was significantly increased in the total group of patients with SLE (p = 0.003). Compared with controls, the patients with NPSLE also presented a significantly increased HLA-DR3 antigen (p = 0.002; RR = 3.03; EF = 0.31). Compared with controls, HLA-DR4 specificity was overrepresented in patients with SLE without neuropsychiatric features (p = 0.001; RR = 3.16; EF = 0.44) and underrepresented in patients with NPSLE (p = 0.0005; RR = 0.18; PF = 0.52). Comparisons of HLA class II frequency between patients with and without neuropsychiatric features showed an increased frequency of HLA-DQ9 and HLA-DQ2 (p = 0.0008 and p = 0.005 respectively) and a decreased frequency of HLA-DQA4 antigens (p < 0.0001) in patients with NPSLE. In patients with NPSLE, the comparisons between diffuse or focal disease with controls or with each other did not disclose significant differences in HLA antigen frequency.

Lymphocytotoxic autoantibodies were detected in 12 of 38 patients with NPSLE with involvement of the central nervous system and in only one of 20 randomly selected patients with non-neuropsychiatric SLE (p = 0.02). All controls were negative. Of the patients with lymphocytotoxic autoantibodies five were HLA-DR9 (all NPSLE), and eight were non-HLA-DR9 (seven NPSLE and one non-NPSLE). Therefore, the presence of lymphocytotoxic autoantibodies was positively associated with the presence of HLA-DR9 (p = 0.04). Only one patient had both lymphocytotoxic autoantibody and HLA-DQ2 antigen (p = 0.2). There were no associations between HLA antigens in NPSLE and other laboratory variables shown in table 1.

Compared with controls, the frequency of the combination of antigens HLA-DR3/4 was increased in non-NPSLE patients.

Table 1. Clinical and laboratory features of patients with SLE and subsets

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Neuropsychiatric SLE (n = 42)</th>
<th>Non-neuropsychiatric SLE (n = 51)</th>
<th>Total group SLE (n = 93)</th>
<th>Control (n = 191)</th>
<th>pc Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nephritis</td>
<td>36 (85-7)</td>
<td>30 (58-8)</td>
<td>66 (70-6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthritis</td>
<td>32 (76-2)</td>
<td>47 (92-1)</td>
<td>79 (84-9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Malar rash</td>
<td>17 (40-5)</td>
<td>25 (49)</td>
<td>42 (45-1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Photosensitivity</td>
<td>16 (38-1)</td>
<td>21 (41-2)</td>
<td>37 (39-7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleuritis</td>
<td>15 (35-7)</td>
<td>16 (31-4)</td>
<td>31 (33-3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral ulcers</td>
<td>11 (26-2)</td>
<td>3 (5-9)</td>
<td>14 (15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Discoid rash</td>
<td>9 (21-4)</td>
<td>15 (29-4)</td>
<td>24 (25-8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pericarditis</td>
<td>8 (19-1)</td>
<td>10 (19-6)</td>
<td>18 (19-3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antinuclear antibodies</td>
<td>40 (95-2)</td>
<td>50 (98-1)</td>
<td>90 (96-7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphopenia</td>
<td>32 (76-2)</td>
<td>35 (68-2)</td>
<td>67 (74)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-dsDNA</td>
<td>21 (50-5)</td>
<td>13 (25-5)</td>
<td>34 (36-5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Ro/SSA</td>
<td>15 (35-7)</td>
<td>19 (37-2)</td>
<td>34 (36-5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lymphocytotoxic antibodies</td>
<td>12 (28-5)</td>
<td>1 (1-9)</td>
<td>13 (13-9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-Sm</td>
<td>10 (23-8)</td>
<td>13 (25-7)</td>
<td>23 (24-7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>False positive test for syphilis</td>
<td>9 (21-4)</td>
<td>9 (17-6)</td>
<td>18 (19-3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anticardiolipin antibodies</td>
<td>5 (11-9)</td>
<td>4 (7-9)</td>
<td>9 (9-6)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Relative risk = 2.65; aetiological fraction = 0.27. The p value refers to the comparison of total group of patients vs controls.
Although patients with SLE and controls were from varied ethnic backgrounds, the frequency of white, Afro-European, and black people, and the frequency of HLA antigens in these ethnic groups did not differ significantly between patients and controls. This study showed that HLA-DR3 antigen was also increased in the total group of patients with SLE, in agreement with a previous study. There are few studies correlating HLA antigens and clinical and laboratory defined subsets of SLE. In our series, the HLA-DR3 antigen conferred susceptibility to, whereas HLA-DR4 conferred protection against the development of NPSLE. As HLA-DR4 antigen has been previously associated with protection against the development of renal SLE, and most (85-79%) of our patients with NPSLE presented also nephritis, the question of whether renal SLE could act as a confounder should be considered. For our total group of patients, the frequency of HLA-DR4 antigen in patients with nephritis and controls (42-4% and 36-6% respectively) was not significantly different (uncorrected p = 0.46). In addition, HLA-DR4 frequency did not differ significantly (uncorrected p = 0.35) between patients with and without nephritis (42-4% and 33-3% respectively). For combinations of SLE subsets (presence or absence of neuropsychiatric or renal involvement), the comparisons of HLA-DR4 frequency among these subsets did not disclose any significant association. Therefore, in this study, the negative association between HLA-DR4 antigen and NPSLE was not influenced by concomitant renal SLE.

In the search for immunogenetic features which could confer susceptibility to NPSLE, we compared HLA frequencies between two subsets of patients with NPSLE. Without neuropsychiatric involvement. Both diffuse and focal NPSLE were lumped together because some pathogenetic features described for diffuse disease have also been shown in focal disease. An increased frequency of HLA-DR9 and HLA-DQ2 antigens has not been previously reported in NPSLE. A previous study conducted on Japanese patients with NPSLE showed an increased frequency of HLA-DR1 antigen. We also found a positive association between lymphocytotoxic autoantibody and HLA-DR9 antigen. The following findings may support the role of autoantibodies in the pathogenesis of NPSLE, as well as the relation between lymphocytotoxic antibodies and HLA antigens. Compared with activity in serum, increased antineuronal antibody activity has been detected in the CSF of patients with NPSLE. Lymphocytotoxic antibodies present in the serum samples of patients with NPSLE have shown activity against neurons in the cortex, cerebellum, and caudate nucleus. Antibrain antibodies found in the serum of patients with NPSLE cross react with lymphocytes.

Is immunogenetic susceptibility to neuropsychiatric systemic lupus erythematosus (SLE) different from non-neuropsychiatric SLE?


